Novartis trumps Bristol-Myers Squibb at NICE for chronic CML
This article was originally published in Scrip
Executive Summary
Novartis looks set to dominate the treatment of chronic phase chronic myeloid leukaemia in England and Wales. NICE, the health technology appraisal body, has said a final draft yes to standard dose Glivec (imatinib) and Glivec follow-on, Tasigna (nilotinib), for the first-line treatment of adults with chronic phase Philadelphia-chromosome positive CML. Bristol-Myers Squibb’s Sprycel (dasatinib) has again lost out on a recommendation on grounds of cost.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.